Top 10 U.S. Biopharma Clusters 2026

GEN’s annual ranking of the top U.S. biopharma clusters highlights the regions leading the nation in life sciences competitiveness, with Seattle ranked No. 10 overall in 2026. 

 

The report notes that biopharma cluster growth is being shaped by increased investment from mid-cap biopharma companies, an improving capital-raising environment, and the re-shoring of manufacturing operations across the United States. Rankings were based on five criteria: patients, NIH funding, venture capital funding, laboratory space, and jobs. 

 

Seattle and its suburbs ranked eighth nationally in both NIH funding and venture capital, ninth in lab space, and tenth in jobs and patents, reflecting the region’s continued strength in research and innovation. Seattle’s inclusion among the nation’s top biopharma clusters underscores the Puget Sound region’s growing influence as a life science hub and its potential to attract future investment, talent, and scientific advancement.